We wrote back in August about a huge cohort study — more than 600,000 veterans — that found GLP-1 prescriptions associated with lower rates of substance use disorders, including alcohol. That post ended on a deliberate note: association isn’t proof, and the real test would be a randomized trial. A separate one had already reported results a few months earlier, and it’s worth walking through on its own terms, because it’s a genuinely different kind of evidence.
The trial
Published May 2, 2026 in The Lancet, researchers at Mental Health Center Copenhagen randomized 108 adults with both alcohol use disorder and obesity to once-weekly semaglutide (2.4 mg, the same dose approved for chronic weight management) or placebo, for 26 weeks. Everyone in the trial — both arms — also received standard cognitive behavioral therapy. Eighty-eight participants completed it.
This is the design that a cohort study can’t offer: participants didn’t choose their treatment, and neither did their clinicians. Assignment was random and the trial was double-blind, so the comparison is a much cleaner test of whether semaglutide itself did anything, rather than a test of who tends to get prescribed it.
What it found
At baseline, participants reported an average of 17.2 heavy drinking days per month. Over the trial, the semaglutide group showed a 13.7 percentage point greater reduction in heavy drinking days than placebo (95% CI −22 to −5.4, p=0.0015) — both groups improved, semaglutide improved more. Total alcohol consumption dropped further too, by roughly 467 grams over 30 days more than placebo, and drinks per drinking day fell by about 1.5 units more.
Self-reported drinking is easy to distrust, so it matters that the trial also tracked alcohol biomarkers — phosphatidylethanol, gamma-glutamyl transferase, and mean cell volume — and all three improved significantly more on semaglutide than placebo. That’s independent lab evidence pointing the same direction as what participants said, which is about as good as this kind of outcome measure gets.
Weight, waist circumference, and blood sugar also improved more on semaglutide, which is expected and not really the point — the trial was designed to isolate whether drinking changed, not just weight.
Side effects were mostly gastrointestinal and mild to moderate, similar to what shows up in semaglutide’s weight-management trials. Four participants stopped because of side effects, and one had a serious event — a hospital admission for abdominal pain — and stayed in the trial afterward.
What it doesn’t establish
This is a real randomized trial, which is stronger evidence than the veteran cohort study we covered earlier. It is also small, and small in specific ways that limit how far it generalizes.
Everyone in it had obesity. The trial enrolled people with alcohol use disorder and comorbid obesity — that’s the population semaglutide is approved to treat for weight. Whether the same effect shows up in someone with alcohol use disorder and a body weight in the typical range is a different question this trial doesn’t answer. The researchers themselves called for trials specifically in people without obesity before anyone assumes the result transfers.
It’s one site, in Denmark, and everyone was already seeking treatment. A hundred and eight people at a single mental health center who had already decided to seek help for their drinking is not a representative sample of everyone with alcohol use disorder. Results at other sites, in other health systems, with people who haven’t sought treatment, remain untested.
Everyone also got therapy. Both arms received cognitive behavioral therapy throughout. This trial tells you what semaglutide added on top of CBT — not what semaglutide does on its own, without any concurrent behavioral treatment.
The confidence interval is wide. A 13.7 percentage point effect with a 95% CI spanning −22 to −5.4 is a real, statistically significant result, but the range is broad enough that the true effect could be considerably smaller — or somewhat larger — than the headline number.
None of that makes the finding uninteresting. It’s the first randomized evidence that semaglutide does something to drinking behavior, not just an association that could be explained by who gets prescribed it. It’s also not close to enough evidence to call semaglutide a treatment for alcohol use disorder — established, evidence-based treatments for AUD remain the standard of care, and no GLP-1 medication is approved for this indication.
The compounded-medication caveat, again
The trial used branded semaglutide — Wegovy — at its standard maintenance dose, manufactured under an FDA-approved application. It says nothing about compounded semaglutide, which is prepared by a licensed pharmacy for an individual patient and has not been studied in this trial or any trial like it. If a program or an ad implies the alcohol research applies to a compounded product, that’s the study being stretched past what it covers — see our FAQ for more on how compounded and branded medications differ. This is not something a licensed provider would prescribe a compounded GLP-1 to treat, and it isn’t something we offer or claim to address.
Why we’re following this at all
We’re not an addiction treatment program, and this research doesn’t change that. What it does is add a second, methodologically different data point to a question we flagged in August: does the biology underneath these medications touch reward circuitry beyond appetite? A large observational study said maybe. A small randomized trial now says something similar, with its own separate set of limits. Two imperfect studies pointing the same direction is a stronger signal than either alone — and still short of an answer.
This post is general information, not medical advice. It does not describe a benefit of any NoBsRx program, and it is not a claim that any medication treats alcohol use disorder or any other substance use disorder. Compounded medications are not FDA-approved. Treatment is never guaranteed — eligibility, diagnosis, and every treatment decision are made by independent licensed providers based on an individual clinical assessment, and availability varies by state. If you or someone you know is struggling with alcohol or substance use, please talk to a licensed clinician or contact SAMHSA’s National Helpline at 1-800-662-4357.